Phase III Trial Comparing Granulocyte Colony-Stimulating Factor to Leridistim in the Prevention of Neutropenic Complications in Breast Cancer Patients Treated with Docetaxel/Doxorubicin/Cyclophosphamide: Results of the BCIRG 004 Trial
- 1 October 2002
- journal article
- clinical trial
- Published by Elsevier in Clinical Breast Cancer
- Vol. 3 (4) , 268-275
- https://doi.org/10.3816/cbc.2002.n.030
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Bivalent binding and signaling characteristics of Leridistim, a novel chimeric dual agonist of interleukin-3 and granulocyte colony-stimulating factor receptorsExperimental Hematology, 2001
- Phase II Study of Docetaxel, Doxorubicin, and Cyclophosphamide as First-Line Chemotherapy for Metastatic Breast CancerJournal of Clinical Oncology, 2001
- Phase II Trial of Doxorubicin and Docetaxel Plus Granulocyte Colony-Stimulating Factor in Metastatic Breast Cancer: Eastern Cooperative Oncology Group Study E1196Journal of Clinical Oncology, 2000
- Myelopoietin, an engineered chimeric IL-3 and G-CSF receptor agonist, stimulates multilineage hematopoietic recovery in a nonhuman primate model of radiation-induced myelosuppressionBlood, 2000
- Myelopoietin, a chimeric agonist of human interleukin 3 and granulocyte colony-stimulating factor receptors, mobilizes CD34+ cells that rapidly engraft lethally x-irradiated nonhuman primatesExperimental Hematology, 1999
- Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast CancerJournal of Clinical Oncology, 1999
- Prospective Randomized Trial of Docetaxel Versus Mitomycin Plus Vinblastine in Patients With Metastatic Breast Cancer Progressing Despite Previous Anthracycline-Containing ChemotherapyJournal of Clinical Oncology, 1999
- Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancerPublished by Elsevier ,1999
- Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.Journal of Clinical Oncology, 1998
- Docetaxel (Taxotere®), a review of preclinical and clinical experience. Part IIAnti-Cancer Drugs, 1995